13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico

A Phase 3, Open Label, Single Arm, Multicenter, Trial to Assess The Safety, Tolerability And Immunogenicity Of 13-Valent Pneumococcal Conjugate Vaccine In Healthy Adults Aged => 50 Years of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine in Mexico.

The purpose of this study will be to assess the safety, tolerability, and immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) when given to healthy adults older than 50 years of age who haven't received 23-valent pneumococcal polysaccharide vaccine in Mexico.

Inclusion Criteria:

• Male or female older than 50 years of age
• Eligibility must be determined by medical history, physical exam and clinical judgment
• Able to complete an electronic diary
• Available for duration of study
• Negative pregnancy test for subjects in group 2 age 50 to 64 years
• Practice abstinence or use reliable birth control if age is 50 to 64 years

Exclusion Criteria:

• History of allergic reaction to any vaccine
• Previous vaccination with licensed or experimental pneumococcal vaccine
• S. pneumonia infection within past 5 years before investigational product administration
• Known or suspected immunodeficiency or received treatment including cytotoxic agents or systemic corticosteroids, serious chronic disorder such as malignancy cancer
• Receipt of plasma products or immunoglobulins within 60 days
• Bleeding conditions or diathesis
• Receipt of investigational product within 28 days before study entry
• Other severe acute or chronic medical or psychiatric condition